Eliglustat is an oral inhibitor of glucosylceramide synthase which is used in the therapy of type 1 Gaucher disease. Clinical experience with eliglustat is limited, but it not been linked to serum enzyme elevations during therapy or to instances of clinically apparent acute liver injury.

29668-44-8:

Eliglustat

20989-17-7:

Eliglustat

Specifications:

Intermediate CAS No’s API/End Use Status Purity
S(+)-2-Phenylglycinol 20989-17-7 Eliglustat Commercial NLT 98%
2,3-dihydrobenzo[b][1,4]dioxine-6-carbaldehyde 29668-44-8 Eliglustat Commercial NLT 97%